References
- Kollareddy M, Dzubak P, Zheleva D, et al. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008;152(1):27–33.
- Hochegger H, Hegarat N, Pereira-Leal JB. Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle. Open Biol. 2013;3(3):120185.
- Sarvagalla S, Coumar MS. Structural biology insight for the design of sub-type selective aurora kinase inhibitors. Curr Cancer Drug Targets. 2015;15(5):375–393.
- Carmena M, Earnshaw WC, Glover DM. The dawn of aurora kinase research: from fly genetics to the clinic. Front Cell Dev Biol. 2015;3:73.
- Cheung CH, Coumar MS, Hsieh HP, et al. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs. 2009;18(4):379–398.
- Cheung CH, Sarvagalla S, Lee JY, et al. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011-2013). Expert Opin Ther Pat. 2014;24(9):1021–1038.
- Wissing MD, van Diest PJ, van der Wall E, et al. Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer. Expert Opin Investig Drugs. 2013;22(5):635–661.
- Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C Mater Biol Appl. 2016;60:569–578.
- Zhu Y, Liao L. Applications of nanoparticles for anticancer drug delivery: a review. J Nanosci Nanotechnol. 2015;15(7):4753–4773.
- Rao JP, Geckeler KE. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011;36(7):887–913.
- Elsabahy M, Heo GS, Lim S-M, et al. Polymeric nanostructures for imaging and therapy. Chem Rev. 2015;115(19):10967–11011.
- Ganoth A, Merimi KC, Peer D. Overcoming multidrug resistance with nanomedicines. Expert Opin Drug Deliv. 2015;12(2):223–238.
- Wang Y, Wei X, Zhang C, et al. Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects. Ther Deliv. 2010;1(2):273–287.
- Prados J, Melguizo C, Ortiz R, et al. Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anticancer Agents Med Chem. 2012;12(9):1058–1070.
- Dawidczyk CM, Kim C, Park JH, et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release. 2014;187:133–144.
- Barenholz Y. Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134.
- Damge C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release. 2007;117(2):163–170.
- Kantarjian HM, Martinelli G, Jabbour EJ, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer. 2013;119(14):2611–2619.
- AstraZeneca. Phosphonooxy quinazoline derivatives and their pharmaceutical use WO2004058781. 2004.
- Wilkinson RW, Odedra R, Heaton SP, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007;13(12):3682–3688.
- Pluim D, Beijnen JH, Schellens JH, et al. Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(29):3549–3555.
- Lowenberg B, Muus P, Ossenkoppele G, et al. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011;118(23):6030–6036.
- AstraZeneca. Therapeutic polymeric nanoparticles and methods of making and using same WO2015036792. 2015.
- Kollareddy M, Zheleva D, Dzubak P, et al. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012;30(6):2411–2432.
- Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol. 2011;155(5):561–579.
- Ashton S, Song YH, Nolan J, et al. Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016;8(325):325ra17.
- Bearss DJ. Are accurins the cure for Aurora kinase inhibitors? Sci Transl Med. 2016;8(325):325fs4.